KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Capital Expenditures (2020 - 2025)

Historic Capital Expenditures for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to $243000.0.

  • Recursion Pharmaceuticals' Capital Expenditures fell 9467.34% to $243000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 million, marking a year-over-year decrease of 5490.18%. This contributed to the annual value of $13.7 million for FY2024, which is 1455.46% up from last year.
  • According to the latest figures from Q3 2025, Recursion Pharmaceuticals' Capital Expenditures is $243000.0, which was down 9467.34% from $3.2 million recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Capital Expenditures ranged from a high of $19.4 million in Q1 2021 and a low of $243000.0 during Q3 2025
  • Moreover, its 5-year median value for Capital Expenditures was $4.5 million (2021), whereas its average is $5.7 million.
  • As far as peak fluctuations go, Recursion Pharmaceuticals' Capital Expenditures skyrocketed by 273859.65% in 2021, and later plummeted by 9467.34% in 2025.
  • Quarter analysis of 5 years shows Recursion Pharmaceuticals' Capital Expenditures stood at $4.5 million in 2021, then surged by 78.74% to $8.0 million in 2022, then plummeted by 74.09% to $2.1 million in 2023, then tumbled by 37.2% to $1.3 million in 2024, then plummeted by 81.28% to $243000.0 in 2025.
  • Its Capital Expenditures stands at $243000.0 for Q3 2025, versus $3.2 million for Q2 2025 and $1.8 million for Q1 2025.